Lupus clinical trials at University of California Health
31 in progress, 26 open to eligible people
2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
open to eligible people ages 18-70
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
at UCSF
FT819 in B-cell Mediated Autoimmune Disease
open to eligible people ages 12-70
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus…
at UC Irvine
Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
open to eligible people ages 18-75
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: - How well cenerimod works on top of the…
at UCSD
Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
open to eligible people ages 18-70
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and…
at UCLA UCSD
CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
open to eligible people ages 17 years and up
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus…
at UC Davis
Felzartamab in Participants With Lupus Nephritis
open to eligible people ages 18-75
The goal of this clinical trial is to evaluate the safety and tolerability of felzartamab plus standard of care in participants with refractory Lupus Nephritis (LN).
at UCSD UCSF
Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
open to eligible people ages 18-65
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus …
at UCSF
Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
open to eligible people ages 18-75
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
at UCLA
Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
open to eligible people ages 18-75
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
at UCSD
Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
open to eligible people ages 5-17
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative…
at UCSF
Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
open to eligible people ages 18 years and up
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care…
at UCLA UCSD
Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
open to eligible people ages 18-75
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for…
at UCSD
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
open to eligible people ages 18-99
AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the …
at UCSD
Stopping Hydroxychloroquine in Elderly Lupus Disease
open to eligible people ages 60 years and up
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection…
at UCLA
MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
open to eligible people ages 18-75
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of…
at UCSD
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
open to eligible people ages 18 years and up
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal…
at UC Davis
Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
open to eligible people ages 18-70
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
at UCLA
Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
open to eligible people ages 12-100
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
at UC Irvine
Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
open to eligible people ages 12-100
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic…
at UCSD
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
open to eligible people ages 18-63
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active…
at UCSD
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
open to eligible people ages 18-65
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
at UC Davis UC Irvine
Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
open to eligible people ages 18-100
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
at UC Davis UC Irvine UCLA UCSD
LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
open to eligible people ages 18-100
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
at UC Irvine UCLA
Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
open to eligible people ages 8-20
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided…
at UCSF
Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
open to eligible people ages 18-76
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE)…
at UCLA
VIBRANT: VIB4920 for Active Lupus Nephritis
open to eligible people ages 18 years and up
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
at UC Irvine UCLA UCSD UCSF
GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus
Sorry, in progress, not accepting new patients
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
at UCSD
PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset…
at UCLA
Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients…
at UCSD
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Sorry, in progress, not accepting new patients
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
at UCLA
BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry
Sorry, in progress, not accepting new patients
The purpose of this prospective, observational cohort study is to evaluate the incidence of adverse events of special interest (AESI) and effectiveness in participants with active, autoantibody-positive SLE treated with and without BENLYSTA…
at UCLA
Our lead scientists for Lupus research studies include Mrinalini Sarkar, MD Chelsey J F Smith Sheetal Desai Raymond Hsu Bethany Karl, DO Maureen A. McMahon, MD Kenneth Kalunian Phuong-Chi Pham Yongen Chang Priyanka Iyer, MD Emily Von Scheven Arthur Francis Kavanaugh George Karpouzas Lama Abdelnour Surbhi Singhal Gaurav Gulati, MD.
Last updated: